NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer.
$0.94+0.40%
报价 2026-11-06
市值
$5.7M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -78.8%
$0.93$4.43
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NCNANuCana plc | $5.7M | +0.4% | – | 0% | – | – | – | |
| TCRTAlaunos Therapeutics, Inc. | $6M | -5.4% | -84.3% | -28,133.3% | – | – | – | |
| ACXPAcurx Pharmaceuticals, Inc. | $5.9M | +12.1% | -97.1% | 0% | – | – | – | |
| CNSPCNS Pharmaceuticals, Inc. | $5.7M | -2.2% | +75.9% | 0% | – | – | – | |
| GTBPGT Biopharma, Inc. | $5.6M | -2.6% | -28.1% | 0% | – | – | – | |
| LGVNLongeveron Inc. | $5.5M | +5.8% | +11.1% | 69.8% | – | – | – | |
| PCSAProcessa Pharmaceuticals, Inc. | $5.4M | +4.9% | -32.9% | 0% | – | – | – | |
| IMRNImmuron Limited | $5.4M | -2.2% | – | 64.5% | – | – | – | |
| ICUSeaStar Medical Holding Corporation | $5.3M | -2.1% | +90.0% | 92.6% | – | – | – | |
| 同行中位数 | – | – | -28.1% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 GBP（非美元）暂无季度数据（首次研究运行后填充）。